PE20180160A1 - Sulfonilureas y compuestos relacionados y uso de estos - Google Patents
Sulfonilureas y compuestos relacionados y uso de estosInfo
- Publication number
- PE20180160A1 PE20180160A1 PE2017001395A PE2017001395A PE20180160A1 PE 20180160 A1 PE20180160 A1 PE 20180160A1 PE 2017001395 A PE2017001395 A PE 2017001395A PE 2017001395 A PE2017001395 A PE 2017001395A PE 20180160 A1 PE20180160 A1 PE 20180160A1
- Authority
- PE
- Peru
- Prior art keywords
- sulfonylureas
- compounds
- furan
- heteroaryl
- aryl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 229940100389 Sulfonylurea Drugs 0.000 title abstract 2
- -1 (4-CHLORO-2,6-DIMETHYLPHENYL) CARBAMOYL Chemical class 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 abstract 1
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- RHBMVXBGYGIDJN-UHFFFAOYSA-N furan-2-sulfonamide Chemical compound NS(=O)(=O)C1=CC=CO1 RHBMVXBGYGIDJN-UHFFFAOYSA-N 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/52—Y being a hetero atom
- C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
- C07C311/56—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/52—Y being a hetero atom
- C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
- C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
- C07C311/60—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/38—2-Pyrrolones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/18—Ring systems of four or more rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/64—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE SULFONILUREAS DE FORMULA (I) DONDE W ES O, S O Se; J ES S Y Se; R1 ES CICLOALQUILO, ARILO, HETEROARILO, ENTRE OTROS; R2 ES ARILO, HETEROARILO, HETEROCICLILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-((2,5-DIMETOXIFENIL)CARBAMOIL)-4-(2-HIDROXIPROPAN-2-IL)FURAN-2-SULFONAMIDA; N-((4-CLORO-2,6-DIMETILFENIL)CARBAMOIL)-4-(2-HIDROXIPROPAN-2-IL)FURAN-2-SULFONAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA ACTIVACION DEL INFLAMASOMA DE LA PROTEINA 3 QUE CONTIENE DOMINIO DE PIRINA (NLRP3) SIENDO UTILES EN EL TRATAMIENTO DE TRASTORNOS QUE IMPLICAN INFLAMACION
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2015900507A AU2015900507A0 (en) | 2015-02-16 | Sulfonylureas and related compounds and use of same |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20180160A1 true PE20180160A1 (es) | 2018-01-18 |
Family
ID=56691944
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2021001430A PE20221627A1 (es) | 2015-02-16 | 2016-02-16 | Sulfonilureas y compuestos relacionados y uso de estos |
PE2017001395A PE20180160A1 (es) | 2015-02-16 | 2016-02-16 | Sulfonilureas y compuestos relacionados y uso de estos |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2021001430A PE20221627A1 (es) | 2015-02-16 | 2016-02-16 | Sulfonilureas y compuestos relacionados y uso de estos |
Country Status (31)
Country | Link |
---|---|
US (3) | US10538487B2 (es) |
EP (3) | EP3578547B1 (es) |
JP (2) | JP6929792B2 (es) |
KR (1) | KR20170109678A (es) |
CN (3) | CN113563264A (es) |
AU (3) | AU2016222278B2 (es) |
BR (1) | BR112017017610A2 (es) |
CA (1) | CA2975192A1 (es) |
CL (2) | CL2017002097A1 (es) |
CY (1) | CY1122832T1 (es) |
DK (2) | DK3578547T3 (es) |
ES (2) | ES2881228T3 (es) |
HK (1) | HK1249501A1 (es) |
HR (2) | HRP20200214T1 (es) |
HU (1) | HUE055755T2 (es) |
IL (2) | IL273065B2 (es) |
LT (2) | LT3259253T (es) |
MA (3) | MA41553B1 (es) |
MD (1) | MD3259253T2 (es) |
ME (1) | ME03737B (es) |
MX (2) | MX2017010528A (es) |
MY (2) | MY197094A (es) |
NZ (2) | NZ772349A (es) |
PE (2) | PE20221627A1 (es) |
PL (2) | PL3259253T3 (es) |
PT (2) | PT3578547T (es) |
RS (2) | RS62164B1 (es) |
RU (1) | RU2739356C2 (es) |
SG (2) | SG11201706664QA (es) |
SI (2) | SI3578547T1 (es) |
WO (1) | WO2016131098A1 (es) |
Families Citing this family (108)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3578547B1 (en) * | 2015-02-16 | 2021-05-26 | The University of Queensland | Sulfonylureas and related compounds and use of same |
FR3046933B1 (fr) * | 2016-01-25 | 2018-03-02 | Galderma Research & Development | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires |
SG11201806745RA (en) | 2016-02-16 | 2018-09-27 | Univ Queensland | Sulfonylureas and related compounds and use of same |
WO2017184624A1 (en) | 2016-04-18 | 2017-10-26 | Ifm Therapeutics, Inc | Compounds and compositions for treating conditions associated with nlrp activity |
WO2018103583A1 (en) * | 2016-12-05 | 2018-06-14 | Zibo Anxuan Pharmaceutical Science And Technology Co., Ltd. | N-hydroxy-benzene-sulfonamide derivatives and their uses thereof |
CA3047336A1 (en) | 2017-01-23 | 2018-07-26 | Jecure Therapeutics, Inc. | Chemical compounds as inhibitors of interleukin-1 activity |
GB2561540A (en) * | 2017-03-13 | 2018-10-24 | Nodthera Ltd | Chemical compounds |
AU2017416068A1 (en) | 2017-05-24 | 2019-10-31 | The Provost, Fellows, Foundation Scholars, And Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Novel compounds and uses |
EP3634951A1 (en) | 2017-06-09 | 2020-04-15 | Cadila Healthcare Limited | Novel substituted sulfoximine compounds |
WO2019008025A1 (en) * | 2017-07-07 | 2019-01-10 | Inflazome Limited | NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS |
EP3649112A1 (en) * | 2017-07-07 | 2020-05-13 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
BR112020000523A2 (pt) * | 2017-07-14 | 2020-07-14 | Innate Tumor Immunity, Inc. | moduladores de nlrp3 |
US11203579B2 (en) | 2017-07-24 | 2021-12-21 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
JP7349981B2 (ja) * | 2017-07-24 | 2023-09-25 | ノバルティス アーゲー | Nlrp活性に関連する状態を治療するための化合物及び組成物 |
GB201712282D0 (en) * | 2017-07-31 | 2017-09-13 | Nodthera Ltd | Selective inhibitors of NLRP3 inflammasome |
US20200361895A1 (en) * | 2017-08-15 | 2020-11-19 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
EP3668840A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
JP2020531453A (ja) | 2017-08-15 | 2020-11-05 | インフレイゾーム リミテッド | Nlrp3阻害剤としてのスルホニルウレアおよびスルホニルチオウレア |
MX2020001778A (es) | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Nuevos compuestos de sulfonamida carboxamida. |
EP3668862A1 (en) * | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
WO2019034693A1 (en) * | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
UY37848A (es) * | 2017-08-15 | 2019-03-29 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 |
WO2019043610A1 (en) | 2017-08-31 | 2019-03-07 | Cadila Healthcare Limited | NEW SUBSTITUTED SULFONYLUREA DERIVATIVES |
US11623922B2 (en) | 2017-10-03 | 2023-04-11 | Inflazome Limited | Compounds |
WO2019092172A1 (en) * | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
SG11202003984UA (en) * | 2017-11-09 | 2020-05-28 | Inflazome Ltd | Novel sulfonamide carboxamide compounds |
US20200354341A1 (en) * | 2017-11-09 | 2020-11-12 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
GB201721185D0 (en) * | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
EP3759089A1 (en) * | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
US11834433B2 (en) | 2018-03-02 | 2023-12-05 | Inflazome Limited | Compounds |
WO2019166619A1 (en) * | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
US11884645B2 (en) | 2018-03-02 | 2024-01-30 | Inflazome Limited | Sulfonyl acetamides as NLRP3 inhibitors |
US20200407340A1 (en) | 2018-03-02 | 2020-12-31 | Inflazome Limited | Sulfonamide derivates as nlrp3 inhibitors |
GB201803393D0 (en) * | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
US11530200B2 (en) | 2018-03-02 | 2022-12-20 | Inflazome Limited | Compounds |
JP7229565B2 (ja) | 2018-03-21 | 2023-02-28 | オラテック セラピューティクス リミティド ライアビリティ カンパニー | メラノーマを治療するための方法 |
AU2019261274B2 (en) | 2018-04-23 | 2021-10-28 | Corcept Therapeutics, Inc. | Methods of preparing regioselective N-alkyl triazoles |
GB201806578D0 (en) | 2018-04-23 | 2018-06-06 | Inflazome Ltd | Novel compound |
CN112533913A (zh) | 2018-05-04 | 2021-03-19 | 英夫拉索姆有限公司 | 新颖化合物 |
CN108404117B (zh) * | 2018-05-29 | 2020-06-30 | 广东龙帆生物科技有限公司 | 核苷酸结合寡聚化结构域样受体蛋白在治疗寨卡病毒感染药物中的应用 |
WO2020010143A1 (en) | 2018-07-03 | 2020-01-09 | Novartis Inflammasome Research, Inc. | Nlrp modulators |
AU2019299444A1 (en) * | 2018-07-03 | 2021-01-14 | Novartis Ag | Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a NLRP3 antagonist |
CN113613721A (zh) * | 2018-07-03 | 2021-11-05 | 诺华股份有限公司 | Nlrp调节剂 |
PE20211049A1 (es) | 2018-07-20 | 2021-06-04 | Hoffmann La Roche | Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1 |
CA3105521A1 (en) * | 2018-07-20 | 2020-01-23 | F. Hoffmann-La Roche Ag | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
GB201902327D0 (en) * | 2019-02-20 | 2019-04-03 | Inflazome Ltd | Novel compounds |
AU2019322546A1 (en) | 2018-08-15 | 2021-03-04 | Inflazome Limited | Novel sulfonamideurea compounds |
GB201817038D0 (en) * | 2018-10-19 | 2018-12-05 | Inflazome Ltd | Novel processes |
EP3870565A1 (en) | 2018-10-24 | 2021-09-01 | Novartis AG | Compounds and compositions for treating conditions associated with nlrp activity |
CN113166081A (zh) * | 2018-11-13 | 2021-07-23 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
CN113015730A (zh) * | 2018-11-13 | 2021-06-22 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
MA54229A (fr) * | 2018-11-13 | 2022-02-16 | Novartis Ag | Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp |
CN113227055A (zh) * | 2018-11-16 | 2021-08-06 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
JP2022507506A (ja) * | 2018-11-16 | 2022-01-18 | ノバルティス アーゲー | Nlrp活性に関連する状態を治療するための化合物及び組成物 |
GB201819083D0 (en) * | 2018-11-23 | 2019-01-09 | Inflazome Ltd | Novel compounds |
EP3911631A4 (en) | 2019-01-14 | 2022-09-28 | Cadila Healthcare Limited | NEW SUBSTITUTED SULFONYLUREA DERIVATIVES |
EP3914583A1 (en) * | 2019-01-22 | 2021-12-01 | Novartis AG | Compounds and compositions for treating conditions associated with nlrp activity |
CA3126495A1 (en) * | 2019-01-25 | 2020-07-30 | NodThera Limited | Carbamate derivatives and uses thereof |
MX2021010098A (es) | 2019-02-22 | 2021-09-28 | Pi Industries Ltd | Un proceso para la sintesis de compuestos de diamida antranilica y compuestos intermedios de los mismos. |
WO2020178441A1 (en) * | 2019-03-06 | 2020-09-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Inhibitors of ngal protein |
GB201905265D0 (en) * | 2019-04-12 | 2019-05-29 | Inflazome Ltd | Inflammasome inhibition |
CN111848461A (zh) * | 2019-04-29 | 2020-10-30 | 苏州大学 | Nlrp3炎症小体抑制剂及其制备方法和应用 |
EP3983388A1 (en) * | 2019-06-12 | 2022-04-20 | Nodthera Limited | Sulfonamide derivatives and uses thereof |
WO2020254697A1 (en) | 2019-06-21 | 2020-12-24 | Ac Immune Sa | Fused 1,2 thiazoles and 1,2 thiazines which act as nl3p3 modulators |
WO2021002887A1 (en) | 2019-07-02 | 2021-01-07 | Novartis Inflammasome Research, Inc. | Gut-targeted nlrp3 antagonists and their use in therapy |
JP2022541514A (ja) * | 2019-07-17 | 2022-09-26 | ズーマゲン バイオサイエンシーズ エルティーディー | Nlrp3モジュレーター |
WO2021009566A1 (en) * | 2019-07-17 | 2021-01-21 | Zomagen Biosciences Ltd | N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran -2-sulfonamide derivatives and related compounds as nlpr3 modulators for the treatment of multiple sclerosis (ms) |
JP2022545400A (ja) * | 2019-08-16 | 2022-10-27 | インフレイゾーム リミテッド | Nlrp3阻害剤として有用な大環状スルホニル尿素誘導体 |
JP2022547882A (ja) * | 2019-09-06 | 2022-11-16 | インフレイゾーム リミテッド | Nlrp3阻害剤 |
EP4027986A4 (en) * | 2019-09-12 | 2023-10-04 | Zydus Lifesciences Limited | NEW SUBSTITUTED SULFOXIMINE DERIVATIVES |
WO2021089776A1 (en) * | 2019-11-07 | 2021-05-14 | Inflazome Limited | Treatment and prevention of a traumatic brain disorder |
GB201916237D0 (en) * | 2019-11-07 | 2019-12-25 | Inflazome Ltd | Novel treatment |
EP4076441A2 (en) * | 2019-11-07 | 2022-10-26 | Inflazome Limited | Treatment and prevention of a neurodegenerative disorder |
CN114599356A (zh) * | 2019-11-07 | 2022-06-07 | 英夫拉索姆有限公司 | 自身炎症性病症的治疗 |
WO2021089781A1 (en) * | 2019-11-07 | 2021-05-14 | Inflazome Limited | Treatment or prevention of psychiatric brain disorders using the nlrp3 inhibitor n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1 -isopropyl-1 h-pyrazole-3-sulfonamide |
CN114630664A (zh) * | 2019-11-07 | 2022-06-14 | 英夫拉索姆有限公司 | 神经炎症或炎性脑部病症的治疗和预防 |
AU2020383646B2 (en) * | 2019-11-12 | 2023-10-12 | Chengdu Baiyu Pharmaceutical Co., Ltd. | Amide derivative and preparation method therefore and use thereof in medicine |
WO2021111351A1 (en) * | 2019-12-03 | 2021-06-10 | Cadila Healthcare Limited | Novel substituted sulfonylurea and sulfoximineurea derivatives |
KR20220131534A (ko) * | 2020-01-22 | 2022-09-28 | 에프. 호프만-라 로슈 아게 | Nlrp3 조절제로서의 술폰이미드아미드 화합물 |
CN115362152A (zh) | 2020-02-18 | 2022-11-18 | 英夫拉索姆有限公司 | 化合物 |
WO2021188450A1 (en) | 2020-03-16 | 2021-09-23 | Zomagen Biosciences Ltd | Nlrp3 modulators |
CN111358778A (zh) * | 2020-03-17 | 2020-07-03 | 中国医科大学附属第一医院 | Mcc950在制备预防或治疗阿尔茨海默病的药物中的应用 |
WO2021185912A1 (en) | 2020-03-19 | 2021-09-23 | Softhale Nv | Method for the treatment nlrp3-associated diseases |
CN115768749B (zh) * | 2020-06-11 | 2024-04-19 | 辰欣药业股份有限公司 | 二甲基亚磺酰亚胺衍生物 |
CA3178361A1 (en) | 2020-06-19 | 2021-12-23 | Emanuele Gabellieri | Dihydrooxazole and thiourea derivatives modulating the nlrp3 inflammasome pathway |
WO2022022646A1 (zh) * | 2020-07-29 | 2022-02-03 | 南京明德新药研发有限公司 | 含硒五元杂芳环化合物 |
WO2022023907A1 (en) | 2020-07-31 | 2022-02-03 | Novartis Ag | Methods of selecting and treating patients at elevated risk of major adverse cardiac events |
WO2022098108A1 (ko) * | 2020-11-04 | 2022-05-12 | (주) 업테라 | Nlrp3 단백질 분해 유도 화합물 |
FR3115682B1 (fr) * | 2020-11-05 | 2023-02-24 | Roquette Freres | Compositions à base de méthyl-cyclodextrines pour le traitement et/ou la prévention de la stéatose hépatique |
EP4251630A1 (en) * | 2020-11-25 | 2023-10-04 | Venatorx Pharmaceuticals, Inc. | Sulfonyl urea nlrp3 inflammasome inhibitors |
KR20220112329A (ko) * | 2021-02-03 | 2022-08-11 | 환인제약 주식회사 | 알츠하이머병 치료를 위한 nlrp3 인플라마좀 소분자 억제제 |
CN117279903A (zh) * | 2021-02-10 | 2023-12-22 | 杭州英创医药科技有限公司 | 作为nlrp3抑制剂的化合物 |
IT202100011237A1 (it) | 2021-05-03 | 2022-11-03 | Univ Degli Studi Di Torino | Composti inibitori dell’inflammasoma nlrp3 e loro uso |
CN116635374A (zh) * | 2021-05-10 | 2023-08-22 | 成都百裕制药股份有限公司 | 酰胺衍生物及其应用 |
TWI815439B (zh) * | 2021-05-10 | 2023-09-11 | 大陸商成都百裕製藥股份有限公司 | 醯胺衍生物及其應用 |
WO2022237782A1 (zh) * | 2021-05-10 | 2022-11-17 | 成都百裕制药股份有限公司 | 酰胺衍生物及其应用 |
EP4359386A1 (en) | 2021-06-23 | 2024-05-01 | F. Hoffmann-La Roche AG | A crystalline potassium salt of 1-ethyl- n -((1,2,3,5,6,7-hexahydro- s -indacen-4-yl)carbamoyl)piperidine-4 -sulfonamide |
ES2948511A1 (es) * | 2021-09-08 | 2023-09-13 | Fundacion Para La Investigacion Biomedica Del Hospital Univ De La Princesa | Derivados de n-sulfonilureas y su uso terapeutico |
KR20230066899A (ko) | 2021-11-08 | 2023-05-16 | 제일약품주식회사 | Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
WO2023098612A1 (zh) * | 2021-12-03 | 2023-06-08 | 南京明德新药研发有限公司 | 二甲基亚磺酰亚胺衍生物的盐型及晶型 |
WO2023118521A1 (en) | 2021-12-22 | 2023-06-29 | Ac Immune Sa | Dihydro-oxazol derivative compounds |
US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
WO2023230002A1 (en) * | 2022-05-23 | 2023-11-30 | VenatoRx Pharmaceuticals, Inc. | Nlrp3 inflammasome inhibitors |
WO2024010772A1 (en) * | 2022-07-06 | 2024-01-11 | Kodiak Sciences Inc. | Nlrp3 inhibitors |
WO2024013395A1 (en) | 2022-07-14 | 2024-01-18 | Ac Immune Sa | Pyrrolotriazine and imidazotriazine derivatives as modulators of the nlrp3 inflammasome pathway |
WO2024023266A1 (en) | 2022-07-28 | 2024-02-01 | Ac Immune Sa | Novel compounds |
KR20240022938A (ko) | 2022-08-12 | 2024-02-20 | 제일약품주식회사 | Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
CN115772173B (zh) * | 2022-12-20 | 2024-04-16 | 武汉国粹医药科技有限公司 | 苯并呋喃类化合物、其制备方法及其应用和抗菌剂 |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB797474A (en) | 1955-07-20 | 1958-07-02 | Boehringer & Soehne Gmbh | Sulphonylurea derivatives |
US3242174A (en) | 1962-02-06 | 1966-03-22 | Pfizer & Co C | 1-(tertiary aminosulfonyl)-3-(hydrocarbon) ureas |
US3305556A (en) | 1962-11-23 | 1967-02-21 | Pfizer & Co C | Novel hypoglycemic agents |
NL129208C (es) | 1965-07-14 | |||
CH509991A (de) | 1966-08-08 | 1971-07-15 | Hoffmann La Roche | Verfahren zur Herstellung von Sulfonamiden |
NL131473C (es) | 1966-10-28 | |||
BE754588A (fr) | 1969-08-07 | 1971-02-08 | Hoechst Ag | Thiophene-sulfonyl-urees et les medicaments qui contiennent cessubstances |
FR2063472A5 (es) | 1969-10-17 | 1971-07-09 | Mercier Pierre | |
GB1477664A (en) * | 1974-04-17 | 1977-06-22 | Christiaens Sa A | Pyridine derivatives |
AU571869B2 (en) | 1983-05-09 | 1988-04-28 | E.I. Du Pont De Nemours And Company | Pyridyl- and pyrimidyl- sulphonamides |
EP0126711B1 (de) | 1983-05-16 | 1989-08-02 | Ciba-Geigy Ag | Herbizid wirksame und pflanzenwuchsregulierende Pyrimidin-Derivate, deren Herstellung und Verwendung |
JPS6045573A (ja) | 1983-08-22 | 1985-03-12 | Nissan Chem Ind Ltd | ピラゾ−ルスルホニルウレア誘導体,その製法および該誘導体を含有する選択性除草剤 |
US4723991A (en) | 1984-03-23 | 1988-02-09 | E. I. Du Pont De Nemours And Company | Lower alkyl 2-[[N-(3-cyano-pyridin-2-yl)aminocarbonyl]aminosulphonyl]benzoate derivatives having herbicidal activity |
US4659369A (en) | 1984-08-27 | 1987-04-21 | E. I. Du Pont De Nemours And Company | Herbicidal acetals and ketals |
AU578307B2 (en) | 1984-09-17 | 1988-10-20 | E.I. Du Pont De Nemours And Company | Herbicidal pyrazolesulfonamides |
FI855180A (fi) | 1985-01-18 | 1986-07-19 | Nissan Chemical Ind Ltd | Pyrazolsulfonamidderivat, foerfarande foer dess framstaellande och det innehaollande ograesgift. |
JPH0720957B2 (ja) | 1985-11-26 | 1995-03-08 | 日産化学工業株式会社 | ピラゾ−ルスルホニルウレア誘導体、製法および除草剤 |
JP2570686B2 (ja) | 1985-12-23 | 1997-01-08 | 日産化学工業株式会社 | ピラゾ−ル誘導体 |
US4830660A (en) | 1986-06-19 | 1989-05-16 | Nissan Chemical Industries, Ltd. | Imidazolesulfonamide derivatives and herbicides |
EP0262096B1 (de) | 1986-09-26 | 1992-01-02 | Ciba-Geigy Ag | Aminopyrazinone und Aminotriazinone |
US4802908A (en) | 1987-01-22 | 1989-02-07 | E. I. Du Pont De Nemours And Company | Herbicidal 2-(1H)-pyrazinones |
WO1991010668A1 (en) | 1990-01-22 | 1991-07-25 | E.I. Du Pont De Nemours And Company | Herbicidal sulfonylureas |
IL98784A0 (en) | 1990-07-17 | 1992-07-15 | Lilly Co Eli | Heterocyclyl sulfonamide derivatives,process for their preparation and pharmaceutical compositions containing them |
US5472933A (en) | 1990-08-29 | 1995-12-05 | E. I. Du Pont De Nemours And Company | Herbicidal pyrrolesulfonylureas |
US5214206A (en) * | 1990-11-07 | 1993-05-25 | Warner-Lambert Company | Aminosulfonyl urea acat inhibitors |
DE4039733A1 (de) | 1990-12-13 | 1992-06-17 | Basf Ag | Substituierte 5-aminopyrazole |
AU2496492A (en) | 1991-08-19 | 1993-03-16 | E.I. Du Pont De Nemours And Company | Angiotensin ii receptor blocking imidazolinone derivatives |
AU2494792A (en) | 1991-08-19 | 1993-03-16 | E.I. Du Pont De Nemours And Company | Angiotensin ii receptor blocking imidazolinone derivatives |
US5169860A (en) * | 1992-03-13 | 1992-12-08 | Eli Lilly And Company | Antitumor compositions and methods of treatment |
US5219856A (en) | 1992-04-06 | 1993-06-15 | E. I. Du Pont De Nemours And Company | Angiotensin-II receptor blocking, heterocycle substituted imidazoles |
JPH0645573A (ja) | 1992-07-23 | 1994-02-18 | Nikon Corp | 赤外線固体撮像装置 |
JPH06199054A (ja) | 1992-12-28 | 1994-07-19 | Dainippon Printing Co Ltd | 熱転写シート |
JPH06199053A (ja) | 1992-12-28 | 1994-07-19 | Sankyo Kagaku Kk | 感熱転写記録用色素 |
JPH06199047A (ja) | 1993-01-08 | 1994-07-19 | New Oji Paper Co Ltd | 感熱記録体 |
US5466823A (en) * | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
AU7007696A (en) | 1995-09-22 | 1997-04-09 | E.I. Du Pont De Nemours And Company | Arthropodicidal 1,4-dihydropyridines and 1,4-dihydropyrimidines |
US5814631A (en) | 1995-09-28 | 1998-09-29 | Suntory Limited | Quinazoline derivatives and applications thereof |
CA2247286A1 (en) * | 1996-02-26 | 1997-08-28 | Hirohiko Hasegawa | Sulfonylureidopyrazole derivatives |
WO1998032733A1 (en) * | 1997-01-29 | 1998-07-30 | Pfizer Inc. | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity |
US6022984A (en) | 1998-07-27 | 2000-02-08 | Pfizer Inc. | Efficient synthesis of furan sulfonamide compounds useful in the synthesis of new IL-1 inhibitors |
JP2000053649A (ja) | 1998-08-11 | 2000-02-22 | Sumitomo Pharmaceut Co Ltd | スルホニルウレイドピラゾール誘導体 |
EP0987552A3 (en) * | 1998-08-31 | 2000-06-07 | Pfizer Products Inc. | Diarylsulfonylurea binding proteins |
DK1178958T3 (da) | 1999-03-15 | 2004-06-21 | Axys Pharm Inc | N-cyanomethylamider som proteaseinhibitorer |
EP1214087A1 (en) * | 1999-09-14 | 2002-06-19 | Pfizer Products Inc. | Combination treatment with il-1ra and compounds that inhibit il-1 processing and release |
US6906063B2 (en) | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
US20020025961A1 (en) | 2000-02-04 | 2002-02-28 | Scarborough Robert M. | Platelet ADP receptor inhibitors |
GB0017676D0 (en) | 2000-07-19 | 2000-09-06 | Angeletti P Ist Richerche Bio | Inhibitors of viral polymerase |
CA2369967A1 (en) * | 2001-02-12 | 2002-08-12 | Joseph Anthony Cornicelli | Methods of treating nuclear factor-kappa b mediated diseases and disorders |
JP2004536063A (ja) | 2001-05-18 | 2004-12-02 | ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬の製造における組み合わせたnep/mp−抑制活性を有する化合物の使用 |
AR037097A1 (es) | 2001-10-05 | 2004-10-20 | Novartis Ag | Compuestos acilsulfonamidas, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento |
FI110677B (fi) | 2001-10-12 | 2003-03-14 | Jujo Thermal Oy | Lämpöherkkä tallennusmateriaali |
SI1441734T1 (sl) | 2001-10-26 | 2007-08-31 | Angeletti P Ist Richerche Bio | Dihidropirimidin karboksamidni inhibitorji HIV-integraze |
EP1487457A1 (en) | 2001-11-30 | 2004-12-22 | Pfizer Products Inc. | Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation |
PL372246A1 (en) | 2002-05-28 | 2005-07-11 | 3-Dimensional Pharmaceuticals, Inc. | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions |
WO2005035520A1 (en) | 2003-10-03 | 2005-04-21 | Portola Pharmaceuticals, Inc. | Substituted isoquinolinones |
JP2007507551A (ja) | 2003-10-03 | 2007-03-29 | ポートラ ファーマシューティカルズ, インコーポレイテッド | 2,4−ジオキソ−3−キナゾリニルアリールスルホニル尿素 |
WO2005105777A1 (en) * | 2004-05-05 | 2005-11-10 | Pharmacia & Upjohn Company Llc | Substituted thiophene amide compounds for the treatment of inflammation |
EP1812429A4 (en) | 2004-09-29 | 2010-07-21 | Portola Pharm Inc | SUBSTITUTED 2H-1,3-BENZOXAZIN-4 (3H) -ONE |
AR052900A1 (es) | 2005-02-11 | 2007-04-11 | Astrazeneca Ab | Derivados de tiazol, un metodo para su preparacion, composiciones farmaceuticas que los contienen y su uso en la elaboracion de medicamentos para el tratamiento de enfermedades mediadas por ece-1 |
GB0505539D0 (en) | 2005-03-17 | 2005-04-27 | Novartis Ag | Organic compounds |
DK200600313A (da) | 2006-03-03 | 2006-03-13 | Novo Nordisk As | Treating type 2 diabetes or metabolic syndrome with an interleukin 1beta inhibitor or an interleukin 1beta synthesis or release inhibitor |
WO2007105637A1 (ja) * | 2006-03-10 | 2007-09-20 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
TWI391378B (zh) | 2006-03-16 | 2013-04-01 | Astellas Pharma Inc | 喹啉酮衍生物或其製藥學上可被容許之鹽 |
GB0701426D0 (en) | 2007-01-25 | 2007-03-07 | Univ Sheffield | Compounds and their use |
US8486987B2 (en) | 2007-11-16 | 2013-07-16 | University Of Medicine And Dentistry Of New Jersey | Mechanism-based small-molecule parasite inhibitors |
US8211928B2 (en) * | 2009-05-29 | 2012-07-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
CA2792102C (en) | 2010-03-05 | 2015-06-09 | Kyowa Hakko Kirin Co., Ltd. | Pyrazolopyrimidine derivative |
US9557321B2 (en) * | 2010-11-18 | 2017-01-31 | Kyoto University | Method for screening drugs for suppressing inflammasome activity |
KR20140075698A (ko) | 2011-09-02 | 2014-06-19 | 교와 핫꼬 기린 가부시키가이샤 | 케모카인 수용체 활성 조절제 |
JP6036193B2 (ja) * | 2012-11-09 | 2016-11-30 | 国立大学法人富山大学 | インフラマソーム活性制御剤 |
PL221813B1 (pl) | 2013-02-22 | 2016-05-31 | Univ Medyczny W Lublinie | Pochodne 1-arylo-6-benzenosulfonyloimidazo[1,2-a][1,3,5] triazyny oraz sposób ich otrzymywania |
TW201501713A (zh) | 2013-03-01 | 2015-01-16 | Kyowa Hakko Kirin Co Ltd | 眼炎症性疾病之預防及/或治療劑 |
CN104513239B (zh) | 2014-12-10 | 2017-08-22 | 沈阳药科大学 | 吡唑并[3,4‑c]吡啶‑7‑酮类化合物及其应用 |
WO2016119349A1 (zh) | 2015-01-29 | 2016-08-04 | 中国农业大学 | 一种磺酰脲类、磺酰胺基甲酸酯类化合物的制备方法 |
EP3578547B1 (en) | 2015-02-16 | 2021-05-26 | The University of Queensland | Sulfonylureas and related compounds and use of same |
US10688077B2 (en) | 2015-02-26 | 2020-06-23 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Inflammasome activation in myelodysplastic syndromes |
EP3394080B1 (en) | 2015-12-23 | 2023-06-07 | The University Of British Columbia | Lipid-linked prodrugs |
FR3046933B1 (fr) | 2016-01-25 | 2018-03-02 | Galderma Research & Development | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires |
SG11201806745RA (en) | 2016-02-16 | 2018-09-27 | Univ Queensland | Sulfonylureas and related compounds and use of same |
WO2017184604A1 (en) | 2016-04-18 | 2017-10-26 | Ifm Therapeutics, Inc | Compounds and compositions for treating conditions associated with nlrp activity |
US10080741B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
US10080742B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
WO2017189663A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
US10144729B2 (en) | 2016-05-18 | 2018-12-04 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
WO2017201152A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
AU2017416068A1 (en) | 2017-05-24 | 2019-10-31 | The Provost, Fellows, Foundation Scholars, And Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Novel compounds and uses |
EP3649112A1 (en) | 2017-07-07 | 2020-05-13 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
WO2019008025A1 (en) | 2017-07-07 | 2019-01-10 | Inflazome Limited | NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS |
US20200361895A1 (en) | 2017-08-15 | 2020-11-19 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
EP4246859A3 (en) | 2018-09-27 | 2024-01-03 | Apple Inc. | Radio link monitoring and failure for new radio-unlicensed operation |
GB201819083D0 (en) * | 2018-11-23 | 2019-01-09 | Inflazome Ltd | Novel compounds |
-
2016
- 2016-02-16 EP EP19187141.7A patent/EP3578547B1/en active Active
- 2016-02-16 PE PE2021001430A patent/PE20221627A1/es unknown
- 2016-02-16 RU RU2017128287A patent/RU2739356C2/ru active
- 2016-02-16 ES ES19187141T patent/ES2881228T3/es active Active
- 2016-02-16 NZ NZ772349A patent/NZ772349A/en unknown
- 2016-02-16 MY MYPI2020001281A patent/MY197094A/en unknown
- 2016-02-16 HU HUE19187141A patent/HUE055755T2/hu unknown
- 2016-02-16 MA MA41553A patent/MA41553B1/fr unknown
- 2016-02-16 MD MDE20180009T patent/MD3259253T2/ro unknown
- 2016-02-16 RS RS20210952A patent/RS62164B1/sr unknown
- 2016-02-16 IL IL273065A patent/IL273065B2/en unknown
- 2016-02-16 MA MA47440A patent/MA47440B1/fr unknown
- 2016-02-16 PL PL16751821T patent/PL3259253T3/pl unknown
- 2016-02-16 ES ES16751821T patent/ES2777626T3/es active Active
- 2016-02-16 EP EP21152421.0A patent/EP3888749A1/en active Pending
- 2016-02-16 KR KR1020177025608A patent/KR20170109678A/ko not_active Application Discontinuation
- 2016-02-16 PT PT191871417T patent/PT3578547T/pt unknown
- 2016-02-16 MX MX2017010528A patent/MX2017010528A/es unknown
- 2016-02-16 IL IL253661A patent/IL253661B2/en unknown
- 2016-02-16 PE PE2017001395A patent/PE20180160A1/es unknown
- 2016-02-16 MY MYPI2017001188A patent/MY193765A/en unknown
- 2016-02-16 PT PT167518216T patent/PT3259253T/pt unknown
- 2016-02-16 EP EP16751821.6A patent/EP3259253B1/en active Active
- 2016-02-16 US US15/551,264 patent/US10538487B2/en active Active
- 2016-02-16 DK DK19187141.7T patent/DK3578547T3/da active
- 2016-02-16 CN CN202110865543.XA patent/CN113563264A/zh active Pending
- 2016-02-16 SI SI201631297T patent/SI3578547T1/sl unknown
- 2016-02-16 RS RS20200258A patent/RS60048B1/sr unknown
- 2016-02-16 BR BR112017017610-6A patent/BR112017017610A2/pt active Search and Examination
- 2016-02-16 SG SG11201706664QA patent/SG11201706664QA/en unknown
- 2016-02-16 AU AU2016222278A patent/AU2016222278B2/en active Active
- 2016-02-16 CN CN201680010446.XA patent/CN107428696B/zh active Active
- 2016-02-16 ME MEP-2020-49A patent/ME03737B/me unknown
- 2016-02-16 JP JP2017560843A patent/JP6929792B2/ja active Active
- 2016-02-16 DK DK16751821.6T patent/DK3259253T3/da active
- 2016-02-16 WO PCT/AU2016/050103 patent/WO2016131098A1/en active Application Filing
- 2016-02-16 LT LTEP16751821.6T patent/LT3259253T/lt unknown
- 2016-02-16 PL PL19187141T patent/PL3578547T3/pl unknown
- 2016-02-16 CN CN202110867103.8A patent/CN113582889A/zh active Pending
- 2016-02-16 SI SI201630635T patent/SI3259253T1/sl unknown
- 2016-02-16 SG SG10202002599XA patent/SG10202002599XA/en unknown
- 2016-02-16 LT LTEP19187141.7T patent/LT3578547T/lt unknown
- 2016-02-16 CA CA2975192A patent/CA2975192A1/en active Pending
- 2016-02-16 NZ NZ733948A patent/NZ733948A/en unknown
- 2016-02-16 MA MA056473A patent/MA56473A/fr unknown
-
2017
- 2017-08-15 MX MX2023001647A patent/MX2023001647A/es unknown
- 2017-08-16 CL CL2017002097A patent/CL2017002097A1/es unknown
-
2018
- 2018-06-20 HK HK18107901.3A patent/HK1249501A1/zh unknown
-
2019
- 2019-01-08 CL CL2019000060A patent/CL2019000060A1/es unknown
- 2019-08-07 US US16/535,002 patent/US11130731B2/en active Active
-
2020
- 2020-02-10 HR HRP20200214TT patent/HRP20200214T1/hr unknown
- 2020-03-18 CY CY20201100252T patent/CY1122832T1/el unknown
- 2020-05-26 AU AU2020203464A patent/AU2020203464B2/en active Active
-
2021
- 2021-07-29 HR HRP20211225TT patent/HRP20211225T1/hr unknown
- 2021-08-11 JP JP2021131251A patent/JP2021185159A/ja active Pending
- 2021-08-18 US US17/405,989 patent/US20220112159A1/en active Granted
- 2021-10-28 AU AU2021258033A patent/AU2021258033A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20180160A1 (es) | Sulfonilureas y compuestos relacionados y uso de estos | |
PE20210128A1 (es) | Inhibidores de la ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos | |
CL2018003291A1 (es) | Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018). | |
PE20191755A1 (es) | Derivados de pirazol como inhibidores de malt 1 | |
EA202092896A1 (ru) | Гетероциклические и гетероарильные соединения для лечения болезни гентингтона | |
CY1121938T1 (el) | Αγωνιστες apj 4-υδροξυ-3-(ετερο¶ρυλ)πυριδινο-2-ονης για χρηση στη θεραπεια καρδιαγγειακων διαταραχων | |
PE20161427A1 (es) | Inhibidores heteroarilo de syk | |
EA201792421A1 (ru) | Амидозамещенные производные циклогексана | |
CL2015000942A1 (es) | Compuestos de benceno sustituido. | |
PE20191652A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue | |
UY36056A (es) | “compuestos de heteroarilo o arilo bicíclicos fusionados “. | |
CL2015003569A1 (es) | “compuestos derivados de (aril ó heteroaril)metil-2-(aril, heterociclil, cicloalquil ó alquil)-1,3-dioxan-metoxi-fenil-piperazin-1-il-fenil-heterociclil sustituido; composición farmacéutica que los comprende; su uso en el tratamiento de la fibrosis”. pct | |
PE20200724A1 (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
EA202090119A1 (ru) | Аморфные и кристаллические формы ido-ингибиторов | |
PE20180355A1 (es) | Desacetoxitubulisina h y analogos de esta | |
ECSP21060240A (es) | Inhibidores de la pcsk9 y métodos de uso de los mismos | |
EA202191114A1 (ru) | Производные пиридинилсульфонамида, фармацевтические композиции и их применение | |
EA201892822A1 (ru) | Новые антибактериальные соединения | |
EA201891586A1 (ru) | Антипролиферативные соединения и их фармацевтические композиции и применения | |
EA201890906A1 (ru) | ПРОИЗВОДНЫЕ ХИНОКСАЛИНА И ПИРИДОПИРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ | |
EA202090193A1 (ru) | Кристаллическая форма n-[1-(5-цианопиридин-2-илметил)-1h-пиразол-3-ил]-2-[4-(1-трифторметилциклопропил)фенил]ацетамида | |
EA201992259A1 (ru) | Замещенные n-(1,3,4-оксадиазол-2-ил)арилкарбоксамиды и их применение в качестве гербицидов | |
EA201890534A1 (ru) | Новые аннелированные феноксиацетамиды | |
UY29517A1 (es) | Nueva clase de 4-lactama benzonitrilos, composiciones farmacéuticas que los contienen y aplicaciones | |
EA201900244A1 (ru) | Антибактериальные средства на основе производных ципрофлоксацина |